NCT05001022

A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study of Subcutaneously Administered ALG-020572 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Doses in Healthy Volunteers (Part 1) and Multiple Doses in Subjects With Chronic Hepatitis B (Part 2)

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Aligos Therapeutics · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

A Randomized Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Conditions

• Chronic Hepatitis B

Interventions

Type	Name	Description
DRUG	ALG-020572	Single or multiple doses of ALG-020572
DRUG	Placebo	Single or multiple doses of Placebo

Timeline

• Start date: 2021-09-25
• Primary completion: 2022-07-18
• Completion: 2022-07-18
• First posted: 2021-08-11
• Last updated: 2023-04-25

Locations

3 sites across 2 countries: New Zealand, United Kingdom